Brind.
  1. Researchers presented Phase 3 clinical data at the European Society for Medical Oncology (ESMO) Congress on September 21, 2026.

Eisai Presents Oncology Research at European Society for Medical Oncology Congress

1 report, 1 independent Updated Oct 15
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Eisai announced the presentation of clinical research across its oncology portfolio at the European Society for Medical Oncology Congress 2026. The presentations included findings from Phase 3 LITESPARK-011 and LITESPARK-012 studies regarding LENVIMA-based combination regimens for advanced renal cell carcinoma. Additionally, Eisai shared exploratory biomarker findings from the Phase 3 LEAP-001 study concerning advanced or recurrent endometrial cancer.

From prnewswire.com

Why it matters

Some supportBrind's analysis of the reports

The presentation of new clinical evidence regarding LENVIMA-based treatments could inform future treatment decisions for patients with difficult-to-treat cancers. This research contributes to the ongoing evaluation of Eisai's oncology pipeline.

Researchers presented Phase 3 clinical data at the European Society for Medical Oncology Congress on September 21, 2026.

From prnewswire.com

Who's involved

Keep exploring

Part of

Researchers presented Phase 3 clinical data at the European Society for Medical Oncology (ESMO) Congress on September 21, 2026. All 1 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped